Advanced Practice Providers: Essential Partners in Modern Oncology Care

The beginning of the 21st century marked an inflection point in oncology. Advances in precision medicine, immunotherapy, and targeted therapies have revolutionized cancer treatment and improved patient outcomes. However, these advances have also increased the complexity of care delivery, placing additional demands on the oncology workforce.

As cancer care continues to evolve, the oncology workforce must adapt to meet the demands of modern oncology practice. Advanced practice providers (APPs), including nurse practitioners (NPs) and physician associates (PAs), are increasingly essential members of multidisciplinary oncology teams. This review examines evolving APP practice models, including generalist, specialist, and hybrid approaches, and summarizes evidence supporting their contributions to clinical outcomes, patient satisfaction, operational efficiency, survivorship care, and workforce sustainability.

Oncology care has experienced substantial advances over the past 2 decades. Precision medicine, immunotherapy, targeted therapies, artificial intelligence, and expanded access to genomic and clinical data have transformed cancer diagnosis, treatment selection, toxicity management, patient engagement, and survivorship care. Simultaneously, increasing numbers of newly diagnosed patients and an aging survivor population requiring long-term surveillance have placed unprecedented demands on the oncology workforce.

Nearly 2 million individuals in the United States are diagnosed with cancer annually, while the population of cancer survivors continues to grow.¹ Although the number of practicing oncologists is projected to increase by approximately 7% over the next decade, demand for oncology services is expected to increase at nearly twice that rate.¹ In contrast, the oncology advanced practice provider (APP) workforce is projected to expand substantially, positioning APPs to play an increasingly important role in addressing workforce shortages, improving access to care, and supporting high-quality, patient-centered oncology services.¹^,²

APPs, including nurse practitioners (NPs) and physician associates (PAs), have evolved far beyond the traditional concept of the “physician extender.” Today, APPs provide autonomous clinical decision-making, longitudinal patient management, symptom management, survivorship care, quality improvement, and leadership.

APPs collaborate closely with physicians, oncology nurses, pharmacists, navigators, and social workers to coordinate increasingly complex care. This multidisciplinary approach improves communication, facilitates timely symptom management, enhances treatment adherence, and supports patients throughout diagnosis, active treatment, survivorship, supportive care, and end-of-life care. Across the cancer continuum, APPs provide adaptable, high-value care.

The Oncology APP: Generalist vs Specialist

As oncology has become increasingly complex, APP practice models have evolved accordingly.

Historically, both oncologists and oncology APPs functioned as generalists, managing diverse patient populations across multiple disease sites and treatment modalities. Generalist APPs provide comprehensive care, including diagnostic evaluation, treatment delivery, toxicity management, follow-up care, survivorship, and surveillance. This versatility strengthens operational flexibility, improves patient access, lowers care costs, and promotes continuity of care.

Conversely, specialist APPs focus on specific disease states, treatment modalities, or clinical practice areas. Disease-specific APP models are utilized in some large community oncology practices but are more commonly associated with academic medical centers and comprehensive cancer programs, where patient volume and disease complexity support subspecialized care.

Specialization enables APPs to develop advanced disease-specific expertise, remain current with rapidly evolving therapies, participate in clinical research, contribute to multidisciplinary tumor boards, and serve as educational resources for colleagues, patients, and health care teams.

Practical Considerations for Choosing a Practice Model

The question is not which model is superior, but rather how practices can leverage both to meet patient needs and address projected workforce shortages. Generalists provide breadth, adaptability, and improved access, whereas specialists contribute depth of expertise and leadership in complex areas of oncology care.

Increasingly, community oncology practices and academic cancer centers are adopting hybrid practice models that combine the flexibility of generalist practice with focused disease-site expertise. Hybrid models allow APPs to maintain broad oncology competencies while developing specialized knowledge in areas such as breast oncology, thoracic oncology, gastrointestinal malignancies, survivorship, supportive care, and oral oncology. These models enhance workforce flexibility while improving continuity, efficiency, and professional development.

As oncology continues to increase in complexity, APPs are uniquely positioned to meet expanding patient care needs. Whether functioning as generalists or specialists, APPs improve access to care, enhance patient outcomes, support physician capacity, and contribute substantially to workforce sustainability.

Key Organizational Considerations

• Workforce projections indicate that APPs will become increasingly important in addressing anticipated oncology workforce shortages and rising patient volumes.¹^,²
• Generalist APP models maximize practice flexibility, continuity of care, and patient access.
• Specialist APP models provide advanced expertise needed to navigate rapidly evolving oncology treatments.
• Hybrid practice models capitalize on both the breadth and depth of APP competencies. Optimal deployment depends on practice size, patient demographics, payer mix, and organizational priorities.

Comparative Evidence and Clinical Outcomes

Although direct comparisons between generalist and specialist APP practice models remain limited, existing evidence consistently demonstrates that APP-led oncology care is associated with high patient satisfaction, excellent clinical outcomes, improved access to care, and increased operational efficiency.^3-6

Subspecialty Consult Model Improves Efficiency and Outcomes

A 2024 study presented at the American Society of Clinical Oncology Quality Care Symposium evaluated approximately 1500 inpatient consultations and found that implementation of a disease-specific consult model staffed by oncologists, fellows, and APPs was associated with a 2-day reduction in median hospital length of stay (P < .001), a 1-hour reduction in time to consultation (P = .003), and a decrease in intensive care unit utilization from 27.5% to 16.4% (P < .001). Inpatient productivity increased by approximately 30% without adversely affecting outpatient productivity, although higher 30-day readmission rates warrant additional investigation.³

Patient Satisfaction

Across oncology practice settings, patients consistently report high satisfaction with APP-delivered care, particularly regarding communication, accessibility, education, and time spent with clinicians.^4,5 Qualitative studies demonstrate that patients view APPs as knowledgeable, supportive members of the oncology care team who promote understanding, confidence, and engagement throughout the cancer journey.⁴^,⁵

Clinical Performance

A multisite study comparing clinical practice patterns of APPs and physicians identified modest differences in history taking, referral patterns, and diagnostic testing. Despite these variations, overall quality of care and clinical performance were comparable, supporting the role of APPs as integral members of oncology care teams.⁶

Survivorship Care as a Strategic Opportunity for APP-Led Models

As the number of cancer survivors continues to increase, survivorship care represents a major opportunity for APP-led care models. Reviews of survivorship care delivery emphasize multidisciplinary approaches that address surveillance, symptom management, prevention, psychosocial support, and care coordination.⁷^-¹⁰ APPs are particularly well suited to provide longitudinal survivorship management, improve care coordination, and facilitate transitions between active treatment and long-term follow-up.¹^,⁷^-¹⁰

Across multiple practice settings, APP integration has reduced wait times, expanded new patient capacity, improved survivorship care delivery, and optimized physician productivity without compromising quality.¹¹

The Future of Oncology APPs

As oncology continues to evolve, so will the role of the oncology APP. Precision oncology, cellular therapies, artificial intelligence, remote patient monitoring, and digital health technologies are transforming cancer care. APPs are well positioned not only to implement these innovations but also to evaluate their effects on patient outcomes, quality of care, and operational efficiency through leadership in clinical practice, education, research, and quality improvement.

Beyond direct patient care, APPs are increasingly assuming leadership roles in clinical research, operational excellence, workforce development, and practice transformation, further strengthening the delivery of high-quality oncology care.

Conclusion

As oncology continues to evolve, the question is no longer whether APPs should be integrated into cancer care, but rather how organizations can most effectively deploy their expertise. Whether practicing as generalists, specialists, or within hybrid care models, APPs have become indispensable members of the oncology workforce.

Strategic investment in APP education, mentorship, leadership development, and innovative practice models will be essential to sustaining high-quality, patient-centered cancer care. Rather than debating whether generalist or specialist APPs provide superior care, oncology organizations should determine which workforce model best aligns with their patient populations, organizational priorities, available resources, and long-term strategic goals.

Although additional comparative research is warranted, existing evidence demonstrates excellent clinical outcomes, operational efficiency, and expanded patient access associated with APP integration.^3-6 Ultimately, the future of high-quality oncology care will depend not only on continued therapeutic innovation but also on the strategic integration, development, and full utilization of APPs.

References

1. Kirkwood MK, Balogh EP, Accordino MK, et al. Where have we been and where are we going? the state of the hematology and medical oncology workforce in America. JCO Oncol Pract. 2025;21(12):1775-1785. doi:10.1200/OP-25-00144
2. Forte G. How Improved Health Workforce Projection Models Could Support Policy. Association of American Medical Colleges; 2024. doi:10.15766/rai_pfdisfs9
3. Prsic EH, Deshpande HA, Wei W, Strait M, Chiang AC. General versus disease-specific medical oncology consults and impact on inpatient quality of care. JCO Oncol Pract. 2024;20(suppl 10):321. doi:10.1200/OP.2024.20.10_suppl.321
4. van Dusseldorp L, Groot M, Adriaansen M, van Vught A, Vissers K, Peters J. What does the nurse practitioner mean to you? a patient-oriented qualitative study in oncological/palliative care. J Clin Nurs. 2019;28(3-4):589-602. doi:10.1111/jocn.14653
5. Stahlke S, Rawson K, Pituskin E. Patient perspectives on nurse practitioner care in oncology in Canada. J Nurs Scholarsh. 2017;49(5):487-494. doi:10.1111/jnu.12313
6. Johnson D, Ouenes O, Letson D, et al. A direct comparison of the clinical practice patterns of advanced practice providers and doctors. Am J Med. 2019;132(11):e778-e785. doi:10.1016/j.amjmed.2019.05.004
7. Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379(25):2438-2450. doi:10.1056/NEJMra1712502
8. Jacobs LA, Shulman LN. Follow-up care of cancer survivors: challenges and solutions. Lancet Oncol. 2017;18(1):e19-e29. doi:10.1016/S1470-2045(16)30386-2
9. Jefford M, Howell D, Li Q, et al. Improved models of care for cancer survivors. Lancet. 2022;399(10334):1551-1560. doi:10.1016/S0140-6736(22)00306-3
10. Stefanou AJ, Hendrick L, Allen K, et al. APP-First: a care delivery model designed to increase access and treatment opportunities for patients with gastrointestinal malignancies. Ann Surg Oncol. 2026;33(1):22-23.doi:10.1245/s10434-025-18614-w